It is worth noting that the data, in this case, were collected in 2015 before the first set of ADA guidelines (2017) was published, which recommended the use of SGLT2i or GLP-1 RA in patients with T2DM and ASCVD (22, 27). Here, GLP1R is linked to type 2 diabetes mellitus.